About Us

iCeutica works with pharmaceutical partners to create new branded medicines by combining our proprietary SoluMatrix™ Fine Particle Technology with our partners’ product experience and commercial insights.

The resulting products provide meaningful clinical benefits for patients and have clearly defined pathways to regulatory and commercial success. There are numerous FDA approved and late-stage products in development that utilize our SoluMatrix technology.

iCeutica is also pursuing a multitude of proprietary product and collaboration opportunities in commercially and clinically important areas. In addition to our work with pharmaceutical partners we are advancing our own pipeline of product candidates that address broad indications, including pain and inflammation, oncology, and respiratory diseases.


Osagie has over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding Phoenix IP Ventures, an IP based Merchant Bank, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Osagie led GSK Ventures in concluding thirty (30) worldwide transactions, within a 3 year period, in which he invested various GSK R&D non-progressed assets into a number of companies and/or as the basis of starting new companies.

Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham. Prior to this role at SmithKline, Osagie was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals Inc., (NASDEQ: ENDP). Osagie previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck's International, Manufacturing and Generic Drug Divisions. Osagie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading US Law Firm in the fields of corporate, corporate finance, taxation and intellectual property law.

Osagie is a serial entrepreneur and investor. He was the Founder of Iroko Pharmaceuticals. In addition, he co-Founded Trigenesis Therapeutics Inc., a biopharmaceutical company focused on developing pharmaceutical products for the dermatological market which he sold to a publicly traded pharmaceutical company. In addition, Osagie was the Founder and former Chairman, President & CEO of Ception Therapeutics. Inc., a biopharmaceutical company which was sold to Cephalon (NASDEQ: CEPH).

Osagie is a member of the Board of Overseers of the University of Pennsylvania Law School and the Board of Trustees of the University of Pennsylvania. Osagie holds post-graduate degrees from the London School of Economics and the University of Pennsylvania Law School, is a member of the New York State Bar and has been the I Grant Irey Adjunct Professor at the University of Pennsylvania Law School where he continues to teach a seminar on "Intellectual Property and National Economic Value Creation".

Jeremy P. A. Fletcher is a Managing Partner of Kew Capital. Before founding Kew Capital in 2008, he was a Managing Director at Credit Suisse for 13 years, where he headed up the Bank's global corporate advisory business in Metals and Mining.

Before switching to Investment Banking in 2001, Jeremy was the European Steel Analyst and Chairman of global steel research team. He was ranked #1 in his sector in all the major European and global polls, including Extel, Reuters, Euromoney and Institutional Investor for five years. The global team was also ranked #1 in the first-ever global Institutional Investor poll in 1999/2000. 

Prior to joining CS in 1995, Mr. Fletcher was a strategy consultant for 14 years, focusing on the steel, metal transformation and engineering industries for corporate clients worldwide. He was a founding partner of the consulting boutique, Beddows & Company, now part of the Hatch Consulting Group. He started his career as a lawyer in a medium sized London law firm. Mr. Fletcher received his B.A. in English Literature from Oxford University.

Dr. David C. U'Prichard currently serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries from his base in Philadelphia, US, and as part-time Chief Scientific Officer and member of the Board of Managers of BioMotiv LLC, an evergreen early drug development accelerator company that is the for-profit arm of the Harrington Project for Discovery and Development.  He is also a Partner at Druid BioVentures LLP (Philadelphia), and Chairman of the Executive Board of Stratified Medicine Scotland, a national academic-industry consortium supported by the Government of Scotland.

From 2005 until 2009, he was a Venture Partner at Red Abbey Venture Partners (Baltimore).During 2003 - 2006, he was a Venture Partner for Apax Partners Ltd. (London) and Care Capital LLC (PrincetonFrom 1999 to 2003 he was CEO of 3-Dimensional Pharmaceuticals, Inc., Yardley PA. During that time he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D.

From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U'Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia® and Iressa®.

Previously, Dr. U'Prichard was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983, following an academic career as tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School (1978-83), and his postdoctoral fellowship at Johns Hopkins University (1975-78). Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow.

He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards.

Dr. U'Prichard is Chairman of the Board of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC, Berkeley Heights, NJ) and serves on the Board of Directors of Life Technologies Corp (NASDAQ: LIFE, Carlsbad, CA), and  Angstrom Pharmaceuticals (San Diego, CA).Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association 2004-2005 and has served on the boards of BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and the Bioethics Institute of the University of Pennsylvania.

Dr. U'Prichard is a consultant for Booz & Co., and is a Trustee of the International House of Philadelphia and The Wilma Theater, also in Philadelphia.



Matthew Callahan
President and CEO

Mr Callahan is the founding CEO of iCeutica and a co-inventor of some of the technologies that comprise the SoluMatrix Fine Particle Technology™. Mr Callahan has led the development of the Company's product pipeline and the creation of iCeutica’s product strategy. He has more than 18 years legal, licensing and investment management experience and is also a director of Glycan Bioscience and Orthocell.

Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, clean technology and other sectors. He was General Manager and General Counsel with Australian listed technology and licensing company ipernica (ASX:NEA),where he was responsible for the licensing programs that have generated more than $120M in revenue.


Dr. Bill Bosch
Chief Scientific Officer

Dr. Bosch is a seasoned pharmaceutical executive with more than 20 years of experience in the industry, focusing on applications of nanotechnology to drug product development. Dr Bosch is a co-inventor of the SoluMatrix™ technology and has been instrumental in the development and scale up of the platform.

Prior to joining iCeutica in 2007 he was Director of Pharmaceutical Research at Elan Corporation where he managed the development activities for four commercial products which incorporate nanotechnology. Dr. Bosch was a co-founder of NanoSystems LLC  in 1995 and a co-inventor of NanoCrystal® Technology.


Kristin Midha
Chief Financial Officer

Kristin Midha is responsible for all the finance and administration functions of the company. Prior to joining iCeutica in March 2012 she was the Assistant Controller at C&D Technologies in Blue Bell, PA. Before that she held finance and accounting roles of increasing responsibility at L’Oreal, Honeywell and Ingersoll-Rand. Kristin holds a Master’s in Business Administration from the University of Chicago and a Bachelor of Science in Accounting and International Business from King’s College.


Dr. Satya Bhamidipati
Vice President, Process Development and Engineering

Dr. Bhamidipati brings over 20 years of experience in development and manufacturing of APIs and dosage forms, regulatory CMC activities and has worked on several successful products from early development through approval and launch, globally.

He is responsible for scale-up, manufacturing and engineering design and development. Prior to joining iCeutica in 2014, he was VP of Pharmaceutical Development and Manufacturing at PTC Therapeutics where he had oversight of formulation, process development of API and drug products, analytical development, clinical supplies and manufacturing. Prior to that, he was with Cephalon and prior to that, with Watson Pharmaceuticals in worldwide Product and Process Development, manufacturing roles.

Dr. Bhamidipati earned his B.S. from IIT Kharagpur, India and M.S., Ph.D. from Purdue University, W Lafayette, IN, all in Engineering.


Dr. Paul Nemeth
Senior Vice President Regulatory Affairs, Clinical Development & Quality Assurance

Dr. Nemeth is responsible for the design and execution of clinical programs, regulatory strategies, interactions with regulatory bodies internationally, and quality assurance.  Prior to joining iCeutica in 2011 he was Vice President of Solstice Neurosciences and also served as Global Head of Regulatory Affairs with AstraZeneca.

Dr. Nemeth has been involved in the successful approval of a variety of products in numerous therapeutic areas, including reformulations, line extensions, and products incorporating novel drug delivery technologies.

Corporate Directory

US Corporate Office

3602 Horizon Drive,
Suite 160
King of Prussia, Pennsylvania 19406

US R&D Office

3604 Horizon Drive,
Suite 150
King of Prussia, Pennsylvania 19406

Australian Registered Office

PO Box 214
Joondalup DC, Western Australia 6919

Patent Attorneys

Fish & Richardson
One Marina Park Drive
Boston, Massachusetts 02210

56 Ord Street
West Perth, Western Australia 6005